Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Whether working on dynamic discoveries in the lab, connecting with students and faculty or pursuing his passion for nature photography, acclaimed biomedical researcher John Kuriyan is inspired by his recent move to join Vanderbilt as the new dean of the School of Medicine Basic Sciences and Distinguished University Professor.

https://news.vanderbilt.edu/2023/04/03/new-dean-of-basic-sciences-aims-to-take-vanderbilt-to-the-next-level-in-biomedical-research-drug-discovery/

Mon, 04/03/2023 - 12:00

Cancer_Cell_Biology_Research_Program

Amy Wolf

Locked

Vanderbilt research presented at Cancer Moonshot meet

Vanderbilt Colorectal cancer expert Bob Coffey, MD, was recently invited to present his research to representatives of President Joe Bidenâ€™s reignited Cancer Moonshot initiative.

https://news.vumc.org/2023/12/08/vanderbilt-research-presented-at-cancer-moonshot-meet/

Fri, 12/08/2023 - 12:00

Gastrointestinal_Cancer_Research_Program

Bill Snyder

Locked

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

https://news.vumc.org/2023/10/04/vulnerability-found-in-immunotherapy-resistant-triple-negative-breast-cancer/

Wed, 10/04/2023 - 12:00

Breast_Cancer_Research_Program

Tom Wilemon

Locked

SPORE in Breast Cancer

SPORE in GI Cancer

Karen Winkfield named a fellow of the American Society for Radiation Oncology

Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, has been named a fellow of the American Society for Radiation Oncology.

https://news.vumc.org/2023/08/01/karen-winkfield-named-a-fellow-of-the-american-society-for-radiation-oncology/

Tue, 08/01/2023 - 12:00

Cancer_Health_Outcomes_and_Control_Research_Program

Tom Wilemon

Locked

Study finds new genetic susceptibilities for colon cancer

Vanderbilt researchers at have found new genes that put people at higher risk for colon cancer and rectal cancer.

https://news.vumc.org/2023/09/12/study-finds-new-genetic-susceptibilities-for-colon-cancer/

Tue, 09/12/2023 - 12:00

Cancer_Epidemiology_Research_Program

Tom Wilemon

Locked

Multiple Cancer Types

The purpose of this study is to evaluate the safety and tolerability of:

* casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
* casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage

Disease Sites: Kidney (Renal Cell), Phase I

Phase: I

Investigator: Rini, Brian

NCTID: NCT05536141

Protocol No: VICC-DTURO23168P

Learn More

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

Disease Sites: Not Available

Phase: II

Investigator: Not Available

NCTID: NCT04895722

Protocol No: VICCGI2145

Learn More

Imaging Biomarkers of Lymphatic Dysfunction

Breast

Persons with secondary arm and/or upper quadrant lymphedema following cancer therapies commonly are prescribed complete decongestive therapy as a course of management of their lymphedema. The investigators will perform a repeated-measures cross-over trial to test the hypothesis that mobilization of protein enriched hardened tissue using graded negative pressure therapy in conjunction with complete decongestive therapy (CDT) is more effective to standard CDT alone for secondary lymphedema management.

Disease Sites: Breast

Phase: N/A

Investigator: Donahue, Manus

NCTID: NCT03760744

Protocol No: VICCBRE18156

Learn More

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Vanderbilt research presented at Cancer Moonshot meet